MedinCell S.A. Logo

MedinCell S.A.

Develops long-acting injectable therapies using proprietary technology to impact global health.

MEDCL | PA

Overview

Corporate Details

ISIN(s):
FR0004065605
LEI:
969500R79U6PXCL2FF46
Country:
France
Address:
3 RUE DES FRERES LUMIERE, 34830 JACOU
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

MedinCell S.A. is a clinical and commercial-stage pharmaceutical company specializing in the development of long-acting injectable (LAI) therapies. Leveraging its proprietary drug delivery technology, the company develops a diverse portfolio of controlled-release products across various therapeutic areas. This innovative approach is designed to enhance treatment efficacy, improve patient compliance, and reduce the overall burden of care by providing sustained therapeutic effects from a single injection. MedinCell collaborates with global pharmaceutical partners to advance its pipeline and address unmet medical needs, with a core mission to impact global health by making treatments more efficient and accessible.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-05 13:46
Earnings Release
Informations privilégiées / Autres communiqués
French 310.2 KB
2025-11-05 13:46
Earnings Release
Inside Information / Other news releases
English 215.5 KB
2025-09-22 07:30
Regulatory News Service
Informations privilégiées / Autres communiqués
French 359.5 KB
2025-09-22 07:30
Regulatory News Service
Inside Information / Other news releases
English 263.8 KB
2025-09-12 07:30
Board/Management Information
Informations privilégiées / Autres communiqués
French 189.0 KB
2025-09-12 07:30
Board/Management Information
Inside Information / Other news releases
English 178.3 KB
2025-09-10 21:41
Regulatory News Service
Informations privilégiées / Autres communiqués
French 171.5 KB
2025-09-10 21:41
Regulatory News Service
Inside Information / Other news releases
English 168.1 KB
2025-06-17 17:45
Annual / Quarterly Financial Statement
Inside Information / News release on accounts, results
English 405.2 KB
2025-06-17 17:45
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
French 395.7 KB
2025-06-10 18:00
Report Publication Announcement
Inside Information / Other news releases
English 185.6 KB
2025-06-10 18:00
Report Publication Announcement
Informations privilégiées / Autres communiqués
French 192.0 KB
2025-06-06 18:00
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
French 183.7 KB
2025-05-28 18:00
Report Publication Announcement
Informations privilégiées / Autres communiqués
French 183.1 KB
2025-05-28 18:00
Regulatory News Service
Inside Information / Other news releases
English 156.6 KB

Automate Your Workflow. Get a real-time feed of all MedinCell S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MedinCell S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MedinCell S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-05-02 N/A Other Sell 60,000 600,006.00 EUR

Peer Companies

Adlai Nortye Ltd. Logo
Clinical-stage biopharma developing innovative targeted and immuno-oncology therapies.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
End-to-end biopharma making plasma-derived biologics for immune-compromised patients.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
Developing single-injection gene therapies for prevalent ocular diseases like wet AMD.
United States of America
ADVM
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France
ALDVI
AegirBio AB Logo
Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.
Sweden
AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France
AELIS
AEON Biopharma, Inc. Logo
Developing therapeutic neurotoxins for medical conditions like migraines and cervical dystonia.
United States of America
AEON
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.
Japan
2927
AGENUS INC Logo
Develops antibodies, cell therapies & adjuvants to harness the immune system against cancer.
United States of America
AGEN
AGIOS PHARMACEUTICALS, INC. Logo
Pioneering cellular metabolism therapies for rare, genetically defined diseases like anemias.
United States of America
AGIO

Talk to a Data Expert

Have a question? We'll get back to you promptly.